視神経症治療薬市場:パイプラインレビュー(2019年下半期)

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:GDATA20MY0077)
◆英語タイトル:Optic Neuropathy - Pipeline Review, H2 2019
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GDATA20MY0077
◆発行日:2019年11月25日
◆調査対象地域:グローバル
◆産業分野:製薬
◆ページ数:66
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥228,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥684,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[視神経症治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Optic Neuropathy – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Optic Neuropathy – Pipeline Review, H2 2019, provides an overview of the Optic Neuropathy (Ophthalmology) pipeline landscape.

Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer treating drugs, stress related chemicals, some antibiotics and cyanogens.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Optic Neuropathy – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Optic Neuropathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Optic Neuropathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 2, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Optic Neuropathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Optic Neuropathy (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Optic Neuropathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Optic Neuropathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Optic Neuropathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Optic Neuropathy (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Optic Neuropathy (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Optic Neuropathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

*** レポート目次(コンテンツ)***

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Optic Neuropathy – Overview
Optic Neuropathy – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Optic Neuropathy – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Optic Neuropathy – Companies Involved in Therapeutics Development
Allergan Plc
Antoxis Ltd
Neurizon Pharma GBR
PharmatrophiX Inc
Quark Pharmaceuticals Inc
Recursion Pharmaceuticals Inc
Regenera Pharma Ltd
Regeneron Pharmaceuticals Inc
Optic Neuropathy – Drug Profiles
aflibercept – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brimonidine tartrate implant – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSIC-002 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELN-41 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fab-3H4 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-22A4 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QPI-1007 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPh-201 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Dominant Optic Atrophy – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Neurological and Ophthalmological Diseases – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Optic Neuropathy – Dormant Projects
Optic Neuropathy – Discontinued Products
Optic Neuropathy – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Optic Neuropathy, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Universities/Institutes, H2 2019
Table 4: Products under Development by Companies, H2 2019
Table 5: Products under Development by Universities/Institutes, H2 2019
Table 6: Number of Products by Stage and Target, H2 2019
Table 7: Number of Products by Stage and Mechanism of Action, H2 2019
Table 8: Number of Products by Stage and Route of Administration, H2 2019
Table 9: Number of Products by Stage and Molecule Type, H2 2019
Table 10: Optic Neuropathy - Pipeline by Allergan Plc, H2 2019
Table 11: Optic Neuropathy - Pipeline by Antoxis Ltd, H2 2019
Table 12: Optic Neuropathy - Pipeline by Neurizon Pharma GBR, H2 2019
Table 13: Optic Neuropathy - Pipeline by PharmatrophiX Inc, H2 2019
Table 14: Optic Neuropathy - Pipeline by Quark Pharmaceuticals Inc, H2 2019
Table 15: Optic Neuropathy - Pipeline by Recursion Pharmaceuticals Inc, H2 2019
Table 16: Optic Neuropathy - Pipeline by Regenera Pharma Ltd, H2 2019
Table 17: Optic Neuropathy - Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
Table 18: Optic Neuropathy - Dormant Projects, H2 2019
Table 19: Optic Neuropathy - Discontinued Products, H2 2019

*** 掲載企業 ***

Allergan Plc
Antoxis Ltd
Neurizon Pharma GBR
PharmatrophiX Inc
Quark Pharmaceuticals Inc
Recursion Pharmaceuticals Inc
Regenera Pharma Ltd
Regeneron Pharmaceuticals Inc

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GDATA20MY0077 )"視神経症治療薬市場:パイプラインレビュー(2019年下半期)" (英文:Optic Neuropathy - Pipeline Review, H2 2019)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。